This question resolves YES if, before 2030, there is at least one randomized controlled trial showing that any treatment lowers all-cause mortality or extends lifespan in the general population. Otherwise, it resolves NO.

The study must be a randomized controlled trial. It cannot be an observational or correlational study, or a study done in vitro or in silico.

The results of the study must be published so they are generally available, and the study must be widely agreed to be non-fraudulent (although details of interpretation may differ).

At least 10% of Americans over the age of 65 must be reasonably eligible for the treatment. Eg., if a new drug is discovered which cures pancreatic cancer, it would extend the life of cancer patients, but would not affect the general public.

If the study is on a treatment which is FDA approved as of 2023 (eg. insulin for diabetes, semaglutide for weight loss, beta blockers for high blood pressure), or a close analog, it must extend lifespan 

 the group it is approved for. So, eg., giving metformin to diabetics does not count, but if metformin extended lifespan among people 

Widely used forms of exercise (eg. weightlifting, running) do not count.